Low and high resolution techniques of typing SSP for the HLA system, have the strength and sensibility required to make them essential for the studies of molecular biology by PCR.
HLA-A SBT of a sample from a patient with B cell ALL revealed a sequence electropherogram profile consistent with an indel polymorphism. Serological typing identified HLA-A3 and A24. Subsequent sequencing with allele specific primers detected three alleles: A*030101, A*2402 and an additional allele which differed from A*2402 (A*24mut) by a single nucleotide insertion between nucleotides 363 and 364 in exon 3. HLA A*24mut was not found in the parents or siblings of this individual. Subsequent sequencing of DNA from blast cell and non blast cell populations sorted by flow cytometry revealed A*24mut to be present on blast cells only whilst A*2402 was present on the non blast cell population. Serological typing on cells from the blast cell population revealed that A*24mut was not expressed.
It is unlikely that A*24mut would have been identified by any other molecular typing technique and it is possible that point mutations which result in the loss of expression of HLA may be more common than originally thought. Blast cells that lack HLA which present tumour peptide would escape immune killing and proliferate as a consequence.
SPECIES-SPECIFIC REGULATION OF RAT AND MOUSE IL-4 RECEPTOR EXPRESSION
Anette Bohnert, Christine Weth, Ulrike Kaiser, Holger Hackstein, Ingrid Kloeting, Gregor Bein. Institute of Clinical Immunology and Transfusion Medicine, University of Giessen, Germany plays an important role in shaping immune responses. It's effects depend upon binding to and signalling through the IL-4 receptor complex. Information on the expression and regulation of the IL4R gene is limited.
The proximal promotor region of the rat IL4R gene was determined by sequence alignment with corresponding genomic sequences of the mouse IL4R gene and by direct sequencing of genomic DNA from 7 rat strains. Rat spleen cells were cultivated with and without IL-4, and IL-4 receptor expression was quantified by FACS analysis.
Alignment of the proximal promoter of the rat IL4R gene with the corresponding sequence of the mouse revealed about 88% homology. Despite this strong homology, the essential palindromic STAT6 binding site in the mouse gene (TTCATCTGAA) is absent in the corresponding rat sequence (GTCATCTGGA). Rat IL-4 receptor expression was down-regulated following incubation of spleen cells with IL-4, whereas in murine B cells IL-4 receptor expression is up-regulated by IL-4.
The IL4R genes of rat and mouse have been placed in a different regulatory context during evolution. The different regulation of IL4R genes may also influence the IL-4 driven immune response in a species-specific manner. These and other observations on species-specific regulation of immune response genes may question the value of genetic animal models for the study of multi factorial human immune disorders.
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EVIDENCE FOR AN APPARENT MHC CLASS I TRIPLET IN RHESUS MACAQUES
Corrine M. C. Heijmans, Nel Otting, Riet Noort, Gaby G. M. Doxiadis, Natasja. G de Groot, Nanine de Groot, Ronald E. Bontrop. Biomedical Primate Research Centre in Rijswijk the Netherlands. Department Genetics and Refinement.
The polymorphic equivalent of the HLA-A and -B gene products in rhesus monkeys are named Mamu-A and -B and can be detected bij means of alloantisera. In order to understand if a serotype correlates with Mamu-class I sequences, a panel of well defined MHC serotyped animals was subjected to sequence analysis. These studies illustrate that the Mamu-class I region is incredibly complex, and that rhesus macaques express multiple HLA-A and -B like molecules per haplotype.
The serological typing studies indicated that one rhesus monkey expresses a triplet at its MHC -A locus as well as at its -B locus. This monkey was found positive for the Mamu-A2, -A25, -A26 and -B10, -B23, -B28 antigens. Therefore this female was made part of an intensive breading program to elucidate the segregation profiles of the haplotypes in question. Pedigree analysis demonstrated that the Mamu-A2, -A26 and -B10, -B28 serotypes segregated on one haplotype. This haplotype was inherited in a stable fashion in females whereas in male rhesus macaques a segment of the apparent duplication was inactivated in two independent occasions. The molecular analysis of the MHC class I genes that are encoded by the haplotype with the apparent Mamu class I triplet will be discussed. Fc receptors (Fc R) are potent mediators between the humoral and the cellular branch of the immune response. Three classes of polymorphic Fc R are described. Variation of the genes coding for the Fc RIIIa and Fc RIIIb isoforms proved to be much higher than hitherto assumed. Responsible for the expression of different alloantigens is the variability of six nucleotide positions within exon three.
We cloned and sequenced the genomic DNA as well as the cDNA fragments of the FCGR3B and the FCGR3A region of 19 Caucasian individuals and persecuted seggregation of genomic variants within 2 families along with a GeneScan on a chromosome 1 region close to the Fc R genes. In addition to the well known FCGR3B and FCGR3A alleles nine different variants with single nucleotide exchanges in one or two of the polymorphic positions were found on the genomic DNA of 12 individuals each of them in the presence of the FCGR3B*2 and/or FCGR3B*3 gene. One apparently healthy individual lacked the classical FCGR3A-gene. Six of the variants were detected on the cloned cDNA of three individuals, too. One of the variants led to a misleading PCR typing result. By perfoming GeneScan we could demonstrate, that each of the four siblings in a familiy inherited the same chromosome 1 region from the father while the corresponding region of the other chromosome was not inherited. Three of the children had the same number of repetitive sequences as the mother and they also shared with her mother the FCGR3B*3 allele which was not present in the fourth child and the father. Two FCGR3 variants seggregated from the father to each child, but additional variants were demonstrated in single sibling. In another family we could demonstrate in one child a T230G nucleotide exchange which does not contribute to the known polymorphic positions and which was not found within the parents. In conclusion the FCGR3 variant forms are found on genomic DNA and cDNA as well enhancing the chance to find the variants also on the protein level. There are hints that variant forms are seggregated within families thus indicating that the total number of genes is higher than assumed. The reason for additional new unseggregated variants remains unclear.
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THE ROLE OF MATERNAL SOLUBLE HLA-G PLASMA LEVELS FOR THE OCCURRENCE OF PREGNANCY DISORDERS
Andrea Steinborn1, Vera Rebmann2, Alexander Scharf1, Christof Sohn1 and Hans Grosse-Wilde2 Depart. of Obstetrics and Gynecology, University of Frankfurt1 and Institute of Immunology, University of Essen2
During pregnancy the fetus represents a semi-allograft. Both membrane-bound and soluble forms of the non-classic human leukocyte antigen (HLA)-G protect the fetus from maternal immune attack. To assess the relevance of soluble HLA-G (sHLA-G) levels in the maternal circulation for the occurrence of characteristic pregnancy disorders, we analysed sHLA-G plasma levels of women with normal and pathological pregnancies. Compared to normal pregnancy, significantly increased sHLA-G levels were detected in women delivered preterm because of intrauterine activation (uncontrollable labour, rupture of fetal membranes, cervical insufficiency) and women with Hemolysis-, Elevated Liver enzymes-, Low Platelet count-(HELLP)-syndrome. Contrary to these disorders, the sHLA-G levels in women with placental abruption were more than 3 times lower than in normal pregnancy (p < 0.0001). Nonparametric discriminant analysis showed that women with sHLA-G levels below 9,95 ng/ml had a relative risk of 7.12 for the development of placental abruption during further course of pregnancy. These results suggest, that the occurrence of pregnancy-associated diseases is strongly influenced by maternal sHLA-G plasma levels. EFS Rhône Alpes, Site de Grenoble, France.
In B cells lymphomas, several genetic alterations being responsible for HLA class I loss of expression have been described, most of them including total or partial deletions of the HLA region.
This study was initiated to find out if other mechanisms could be involved at a molecular level in a partial lack of HLA class I expression in B lymphoma cells.
Patients with a decreased HLA expression were selected on the basis of the ratio of B and T lymphocytes class I expression , obtained by Flow Cytometry (w6/32, CD22,CD3 Ab). One patient with a decreased B/T ratio was selected and analysed : The HLA class I typing of this patient was : A*02,*11; B*13,*27. Primers specific for beta2 microglobulin, actin, A locus, B locus and A and B alleles were used in a PCR assay performed on cDNA isolated from CD19+ and CD19-populations : no difference could be detected between the respective amplified products of these populations(agarose gel electrophoresis). Monoallelic sequencing of the A and B expressed alleles in the malignant population was performed : two B*2705 mRNAs were identified , both with a single substitution of G to A at position 555, the minor population having only this substitution, the major one showing an extra deletion of 63 nucleotides at the end of exon 3, probably due to the presence of an extra splicing site. In the genomic DNA extracted from B and T cells, the B*2705 mutation was present in the B but not in the T population.
Conclusion : This example suggests that a single somatic mutation in an HLA allele can be responsible for a loss of HLA expression in cancer cells .
INCREASED SOLUBLE HLA-DR LEVELS IN PREGNANT WOMEN WITH ANTIPHOSHOLIPID SYNDROMES AND THE CORRELATION TO SOLUBLE CD95 LIGAND LEVELS
Vera Rebmann, Elzbieta Ronin-Walknowska1, Olimpia SipakSzmigiel1, Ewa Czajkowska1, and Hans Grosse-Wilde. Institute of Immunology, University Hospital of Essen, Germany, 1Depart. of Path. of Pregnancy, Medical University Szczecin, Poland Anti-phospholipid syndrome (APS) is a severe complication in pregnancy that can lead to fetal death in the second or third trimester. As soluble HLA-DR (sHLA-DR) molecules are reported to be implicated in the etiology of pregnancy disorders and of autoimmune diseases, we studied sHLA-DR plasma levels in pregnant women with APS (N=14), women with normal (N=15), and with high risk pregnancies such as preeclampsia (PE; N=20) and intrauterine growth retardation (IUGR; N=10) and fertile non-pregnant women (N=43). The sHLA-DR levels of pregnant women were assessed during the third trimester, at labor, in the first week, and the third month of puerperium. The results obtained were compared to levels of sCD95 Ligand (sCD95L) an important signal molecule in the apoptosis pathway. sHLA-DR in pregnant women with APS were appr. 3fold higher (mean: 1.48 ± 0.15 SEM µg/ml; p=0.0004) during the whole observation period than in fertile non-pregnant women (0.57 ± 0.13 SEM µg/ml) and in women with normal (0.74+ 0.13 SEM µg/ml) and high risk pregnancies (PE: 0.91 ± 0.14 SEM µg/ml; and IUGR: 0.94 ± 0.21 SEM µg/ml). For sCD95L plasma levels no substantial variations were found among the different groups. In pregnant women with APS, however, sHLA-DR were positively correlated with sCD95L (r = 0.55, p<0,0001). This finding suggests a functional involvement of sHLA-DR molecules in the induction of CD95/CD95L mediated apoptosis pathway that may play a crucial role in the pathology of pregnancies complicated by APS. This study aimed to evaluate the predictive value of a two way FCXM (patient vs donor; donor vs patient) prior to HSCT as an indication of graft outcome. FCXM data was compared to clinical data (GVHD,OS, GF) so that we could formulate an evidence -based strategy for crossmatching prior to transplant.
EVALUATION OF FLOW CYTOMETRIC CROSSMATCHING
Between September 2001 and December 2002 serum samples, routinely collected from HSCT patients and potential donors, were screened for the presence of HLA class I and class II specific antibodies respectively, using the ELISA kits Quikscreen (QS) and B-Screen (QSB) (GTI Inc.). Samples giving a positive result by either test were then investigated further by flow cytometry using FlowPRA Specific beads (One Lambda) to determine the antibody specificity.
All 28 patient sera were antibody negative but 8 out of 53 (15.1%) donor sera were antibody positive (6 with class II, 1 with class I and class II, 1 with class I only.) When tested with Flow PRA beads IgG HLA specific antibodies were defined in only one sample. The remaining 7 samples were negative with the Flow PRA beads; As they had been borderline positives by QS and QSB they were therefore considered to be negative for IgG HLA specific antibodies.
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transplanted but 2 subsequently died, and the remaining 9 will not be considered for transplant.
In conclusion, due to the low sensitisation incidence in the patient and donor populations tested we were unable to find a correlation between FCXM outcome and GVHD / overall survival, as none of the patients who were transplanted had a positive FCXM. Based on this study a comprehensive pre-transplant screening programme will be introduced for patients and donors and subsequently only patients with definable HLA specific antibodies will receive a pre-transplant FCXM. 28 donors (19 males / 9 females) were crossmatched two ways against 21 patients (14 males / 7 females). The 45 antibody negative donor samples were FCXM negative. The one positive crossmatch was obtained for the patient with the antibody positive donor, following a donor vs patient crossmatch. This result correlated with the screening data, as HLA specific antibodies were defined in serum from the donor used in this crossmatch. This patient was later transplanted with an alternative FCXM negative donor (selected due to improved HLA matching criteria) but has since died within 3 months of transplant. Of the remaining 20 patients, 2 died pre-transplant, 9 were
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GENE EXPRESSION ANALYSIS IN NON SMALL CELL LUNG CANCER (NSCLC) USING MICROARRAY TECHNOLOGY.
Paolo Fardin *, Jürg Bähler §, Paolo Capanni*, Erika Inglese*, Annamaria Ricciardi* and Giovanni Battista Ferrara*. * Advanced Biotechnology Center, National Cancer Research Institute; § The Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK Non small cell lung cancer (NSCLC) represents the most frequent histological subtype of all lung tumor cases. The identification of prognostic factors could be very useful to understand lung cancer biology and to develop therapeutic strategies based on new drugs against molecular targets.
Using cDNA microarray, we studied normal and tumoral tissues of five different patients with non small cell lung cancer. RNA samples were extracted from frozen tissues and then labeled cDNAs were synthetized and used for hybridization. In our study we used PAN Human Cancer microarray (MWG) which contains about 2,000 human genes associated with cancer development and progression.
We compared gene expression levels of tumoral sample against the normal one of each patient by the use of data mining softwares and in collaboration with the Wellcome Trust Sanger Institute. The genes of interest have been divided in some families according to their functions and the public database.
The following studies on selected genes are important to choose potential targets for therapeutic strategies. -17, both-17) . This allele, which is essentially a 'hybrid' of A*0301 and A*3201, encodes a heavy chain which has an HLA-A3 alpha 2 domain and an HLA-A32 alpha 1 domain and exhibits both A3 and A32 serological characteristics.
HLA-
The HLA-A3 specificity was reported (or queried) by 13 laboratories, A32 was assigned by 4 and A3/A32 by 4 laboratories; 1 laboratory failed to find a second HLA-A specificity. Interestingly, the HLA-A specificities assigned by laboratories using the single most reported serology typing tray manufacturer included A3 only (n=6), A3/A32 (n=4) and A32 only (n=3). A*3204 was reported by 17 laboratories, while 9 reported A*03 or an A*03 group of alleles, 5 assigned A*32, 2 failed to find a second allele and 1 reported A*0308. A*3204 was queried by 2 laboratories from 'discrepant' serology/DNA findings. Thus overall, 48.7% (n=19) of laboratories correctly identified or queried A*3204 while 10.3% (n=4) reported A32. However, 33.3% (n=13) of laboratories reported A3, and the remainder were either unsure, reporting A3/A32 with no comment (n=2), or missed the second HLA-A allele (n=1). From this exercise it is apparent that over one-third of laboratories are likely to report an incorrect HLA type, at the '2-digit' or specificity level, when confronted with A*3204.
HLA-A*0224 AND ITS TESTING IN AN EXTERNAL QUALITY ASSESSMENT EXERCISE Chris Darke, Susan Corbin and Jonathan Downing
With permission of the UKNEQAS for H&I Steering Committee Welsh Transplantation and Immunogenetics Laboratory, Welsh Blood Service, Pontyclun, Cardiff CF72 9WB
The first two examples of HLA-A*0224 were identified in this laboratory (Tissue Antigens 1999, 53, 190) . A comparison of DNA and serological typing revealed an HLA-A2 by serology that was not detected by PCR-SSP. A*0224 differs from A*0201 by a single base (C/A) at position 453 and this substitution corresponded to the annealing site of a primer (302-Tissue Antigens 1995, 46, 355) commonly used in A*02-amplifying PCR-SSP mixtures. Accordingly we modified our PCR-SSP mixtures to detect A*0224 and differentiate it during high resolution A*02 typing. We have subsequently identified two further examples of A*0224 in our local blood donor population. Interestingly, all four subjects, who are allegedly not closely related, possess: A*0224; B*07; Cw*0702; DRB1*07; DQA1*0201, DQB1*0202, suggesting that this represents a major A*0224-bearing haplotype. One of these was a random previously untyped blood donor tested by 27 laboratories at low resolution (serology only-3, DNA-based only-9, both-15) as part of the UK National External Quality Assessment Schemes for Histocompatibility and Immunogenetics Scheme 1A -HLA Phenotyping. 17/18 laboratories reported an HLA-A2 specificity and 17/24 laboratories assigned A*02 (A*02 or allele group-15, A*0203-1, A*0224-1), however 7 laboratories failed to detect A*02. Although the frequency of A*0224 is likely to be low, the 'take-home' message provided by this event is to ensure that DNA-based HLA typing protocols are able to detect A*0224.
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FINNISH (28 BMT, 25 PBSCT, DLI 11, and CB 1) . Pts' sex distribution was: 68% males vs. 32% females. Median age of the pts was 26 yrs. 51% of donors were selected from own registry and rest from abroad. Donor candidates sex distribution was: 69% males vs. 31% females with median age of was 36 yrs. 83% of all donor candidates were unavailable for confirmatory typing sampling.
The median time needed to select best donor candidate for patient was 65 days. For Finnish patients, the median time to SCT from domestic donor was 99 days and 125 days from foreign donor.
In conclusion, the evaluation shows that we need more young, especially male, donor candidates to participate the Finnish registry. Surprisingly high portion of donor candidates were unavailable. Our donor panel is relatively small, but it's strength is matched phenotype pool for Finnish patients, and it enables faster donation process.
YEARS OF THE CZECH NATIONAL MARROW DONOR REGISTRY /CNMDR/: AN OVERVIEW OF THE ACTIVITY AND FUTURE PROSPECTS
Jindra Pavel, Pilsen, Koza V., Pilsen, Pittrová H., Pilsen, Navrátilová J., Pilsen, Ambruzová Z., Olomouc, Banzetová H., CeskeBudejovice, Bartonícková A., Brno Bohonek M., Prague, Jílková B., Hradec Králové, Cermáková Z., Ostrava Herynková R., Pilsen, Masopust J., Ústí n. Labem, Vyskocilová E., Most Czech National Marrow Donor Registry, Pilsen
The CNMDR launched its activity in the year 1992 in rather a complicated and uneasy situation of the health care system in our country at that time. It was established as an independent, non-governmental and self-supporting non-profit organization. Since the year 1994 it has been participating in BMDW and in the year 1997 an agreement of collaboration with NMDP was signed. In its 10th year of operation it covers all regions of our country with 9 contracted donor centers and operates its own HLA EFI accredited laboratories. The active donor panel consists of over 23 000 volunteers with 60% and 4% of them DRB1*, resp. A*B*DRB1* DNA-typed. Median age of all donors is 33 years, median age of donors recruited in last two years is 28 years. The Registry has over 95% success in search activation /in obtaining DR or Confirmatory Typing samples/ and owing to the stored donor material operates very rapidly. The Registry has provided 97 donations, 57 for domestic and 40 for international pts, and 5 DLI donations since its inception in 1992. At present over 30 donations are provided yearly. Following future strategies, reflecting medical and financial issues, have been set up: 1/ To complete the molecular DR typing of previously recruited donors as much as possible 2/ To increase the number of HLA-A,-B DNA typed donors, especially by DNA retyping of donors with high risk of mistyping by serology 3/ To keep low median age of newly recruited donors with age limit of 35 years for recruitment 4/ To keep all operational standards in compatibility with WMDA standards to be ready for WMDA accreditation any time. Quality management and accreditation standards are essential requisites for proper laboratory diagnostics. These principles are covered by EFI-standards and are established in several laboratories all around Europe. We describe the implementation of a novel improved quality management system for immunogenetic laboratories combining certification of a quality management system according to ISO EN 9001 / EN 46001 and accreditation of laboratory test parameters according to ISO EN 45001 / EN 17025 and EFI-standards. This system includes 20 quality elements based on ISO 9001 and is structured to also fulfill certification of laboratory processes. It is based on a quality management handbook (QMH) describing the laboratory procedures and quality system. The QMH is supplemented by 25 general procedure elements which provide more detail on processes in sample processing, laboratory testing and error detection, including all regulations demanded by the ISO 9001 and EFI standard. Besides the general procedures there are different categories of standard operation proceedings (SOPs) including procedures for operating and maintaining all equipment including the validation of equipment. This improved quality management system for immunogenetic laboratories, which must be maintained and undergo external audit at regular intervals by the certification and accreditation authorities so that certification is confirmed, ensures a high quality level for diagnostic procedures and tests provided to hospitals and patients.
HLA-DRB1 HOMOZYGOSIS IN SPONTANOUS ABORTIONS OF UNCERTAIN GENESIS.
Boldyreva M.N., Chromova N.A, Jankevich T.E., Bogatova O.V., Gouskova I.A., Philippova E.V., Alexeev L.P. Institute of Immunology Russia Ministry of Health Previously reported data obtained among some population isolates in absence of social factors there and as a result an increased number of heterozygous HLAhaplotypes as compared to a theoretically expected one.
The purpose of our study was to analyze DRB1-gene homozygosis in the development of spontaneous abortions of uncertain genesis.We determined homozygotas of different DRB1 specificity among couples with children (n=74), couples with pregnancy problems of uncertain genesis (n=240) and healthy control donor of corresponding sex (97 females and 203 males). DRB1-genotyping was performed using sequence specific primers on low resolution level.
Among women with spontaneous abortions a determined total number of homozygotas as well as homozygotas of different DRB1 specificity did not differ from those determined among both women with children and controls. Among men with children a determined total number of homozygotas was 3 times lower as compared to men from couples with spontaneous abortions and to controls (5,4% against 15,4% p<0,05 and 19,2%, p<0,01 respectively). It should be noted that among 74 couples with children 1 man was DRB1*02 homozygous and 3 men -DRB1*07 homozygous, in other words homozygosis on those specificities did not prevent from successful reproduction. The obtained data suggest different roles of homozygosis among men and women in favorable pregnancy development.
